Immuno-PCR: A high-sensitivity approach for biomarker analysis

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-04-08 DOI:10.1016/j.cca.2025.120289

Hansen Shi , Biyun Zeng , Qiping Wei , Zhu Yuan , Jingjie Peng , Peijun Zhang , Tiancai Liu , Tao Zeng

{"title":"Immuno-PCR: A high-sensitivity approach for biomarker analysis","authors":"Hansen Shi , Biyun Zeng , Qiping Wei , Zhu Yuan , Jingjie Peng , Peijun Zhang , Tiancai Liu , Tao Zeng","doi":"10.1016/j.cca.2025.120289","DOIUrl":null,"url":null,"abstract":"<div><div>The integration of immunology and molecular biology, Immuno-Polymerase Chain Reaction, ie, Immuno-PCR, (iPCR), is an innovative cutting-edge detection strategy that holds significant promise for the identification of pathophysiologic biomarkers present at very low concentration or those inherently unstable. iPCR, known for superior sensitivity and specificity, has proven valuable in early disease diagnosis, monitoring and prognosis. This review summarizes the current applications of iPCR in detecting various disease biomarkers including those related to cancer, infection, autoimmune, cardiovascular, and neurological disease. We introduce the principle, advantages and limitations, specific applications, and clinical significance of iPCR, thereby promoting the widespread application of this technology in disease diagnosis. This technology facilitates early detection and intervention, enhances patient outcomes and survival rates, and is a valuable reference for future research and applications.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"573 ","pages":"Article 120289"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001688","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The integration of immunology and molecular biology, Immuno-Polymerase Chain Reaction, ie, Immuno-PCR, (iPCR), is an innovative cutting-edge detection strategy that holds significant promise for the identification of pathophysiologic biomarkers present at very low concentration or those inherently unstable. iPCR, known for superior sensitivity and specificity, has proven valuable in early disease diagnosis, monitoring and prognosis. This review summarizes the current applications of iPCR in detecting various disease biomarkers including those related to cancer, infection, autoimmune, cardiovascular, and neurological disease. We introduce the principle, advantages and limitations, specific applications, and clinical significance of iPCR, thereby promoting the widespread application of this technology in disease diagnosis. This technology facilitates early detection and intervention, enhances patient outcomes and survival rates, and is a valuable reference for future research and applications.

Abstract Image

查看原文本刊更多论文

免疫pcr：一种高灵敏度的生物标志物分析方法

免疫聚合酶链反应，即免疫pcr，（iPCR）是免疫学和分子生物学的结合，是一种创新的前沿检测策略，对鉴定低浓度或固有不稳定的病理生理生物标志物具有重要的前景。iPCR以其优越的敏感性和特异性，在疾病的早期诊断、监测和预后方面具有重要价值。本文综述了目前iPCR在检测各种疾病生物标志物方面的应用，包括与癌症、感染、自身免疫、心血管和神经系统疾病相关的生物标志物。介绍iPCR的原理、优点和局限性、具体应用及临床意义，从而促进该技术在疾病诊断中的广泛应用。该技术有助于早期发现和干预，提高患者预后和生存率，为未来的研究和应用提供了有价值的参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.